Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
BACKGROUND: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non-small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investigating the recommended phase 2 dose (RP2D) and activity of entrectinib in pediatric patients with solid tumors including primary central nervous system tumors. METHODS: STARTRK-NG (NCT02650401) is a phase 1/2 trial...
October 3, 2022: Neuro-oncology